The influence of whole-body cryotherapy on physiological blood indicators, oxidative stress and selected disease markers in people with multiple sclerosis
- Conditions
- Multiple SclerosisPhysical Medicine / Rehabilitation - PhysiotherapyNeurological - Multiple sclerosis
- Registration Number
- ACTRN12620001142921
- Lead Sponsor
- Bartlomiej Ptaszek
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 45
• diagnosis: multiple sclerosis - ICD10: G35 (confirmed by imaging: magnetic resonance imaging, cerebrospinal fluid examination, examination of visual evoked potentials)
• age: 30 - 55 years old
• Expanded Disability Status Scale - value from 0 to 6
• no contraindications to whole body cryotherapy
• written consent of the patient to participate in the study
• unregulated hypertension
• atherosclerosis
• diabetes
• local blood supply disorders
• bladder and urinary tract diseases
• consuming more than 4 cups of coffee or more than 2 alcoholic beverages per day
• contraindications to the use of whole body cryotherapy
• participation in other forms of physical activity during the study
• no consent to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of changes in rheological properties of blood such as the erythrocyte elongation index (EI), erythrocyte aggregation indexes (AI), i.e. AMP - total aggregation, T1/2 - half time of total aggregation which were determined using Analizator Laser-assisted Optical Rotational Cell Analyser (LORCA) RR Mechatronics.[Baseline and after a series of 20 cryotherapy treatments];Assessment of the change in proteinogram level (total protein, albumin, alpha-1 globulin, alpha-2 globulin, beta-1 globulin, beta-2 globulin, gamma globulin, A / G index) in blood serum. The tests were carried out using the Cobas 6000, Roche analyzer (biuret method) and Minicap Sebia analyzer (capillary method).[Baseline and after a series of 20 cryotherapy treatments];Assessment of hematological parameters of the blood (Hemoglobin, g/dL; Hematocrit, %; Erythrocytes (x1012/L); Leukocyte count (x109/L); Platelet count (x109/L)) using the ABX MICROS 60 hematology analyzer (USA).[Baseline and after a series of 20 cryotherapy treatments]
- Secondary Outcome Measures
Name Time Method